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 Histamine, synthesized by L-histidine decarboxylase (HDC), is a trophic growth 
factor that increases biliary damage/proliferation, inflammation, hepatic fibrosis and 
angiogenesis. Histamine signals through one of four G protein-coupled receptors, H1-H4 
histamine receptors (HRs). Cholangiocytes, the epithelial cells that line the biliary tree of 
the liver, can be subdivided into small (~8 µm in size) and large (~15 µm in size) 
cholangiocytes, which have phenotypical and functional differences. H1HR is primarily 
found on small cholangiocytes, whereas H2HR is predominantly found on large 
cholangiocytes. Mast cells (MCs) (i) infiltrate the liver during cholestasis, (ii) reside near 
large ducts and (iii) release large amounts of histamine that mediates damage. We aimed 
to identify the role of MC-derived histamine on large cholangiocyte damage/proliferation 
via H2HR signaling, and subsequent liver injury in models of cholestasis. 
 We found that bile duct ligation (BDL, a model of cholestasis) induces large 
cholangiocyte damage, concomitant with increased MC infiltration near large ducts, and 
promotes liver inflammation, fibrosis and angiogenesis. MC-deficient mice subjected to 
BDL have reduced large cholangiocyte injury, mediated by decreased H2HR signaling, 
and reduced liver injury. Reintroduction of MCs into MC-deficient mice enhanced large 
cholangiocyte H2HR signaling, with an increase in large duct damage, as well as liver 
inflammation, fibrosis and angiogenesis. Multidrug resistance-2 knockout mice (Mdr2-/- 
mice, a model of primary sclerosing cholangitis) have increased large duct damage 
alongside increased H2HR signaling. Consequently, Mdr2-/- mice show increased liver 
inflammation, fibrosis and angiogenesis. Inhibition of large cholangiocyte H2HR signaling 
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by Vivo Morpholino treatment reduced these parameters. In vitro, MCs preferentially 
migrated towards damaged large, but not small, cholangiocytes. In vitro, large 
cholangiocytes treated with MC supernatants have increased damage and H2HR 
signaling, that is ameliorated when MCs are pre-treated with an HDC inhibitor (to block 
MC-derived histamine). 
 In conclusion, MC-derived histamine promotes large duct damage during 
cholestasis via H2HR signaling. Increased hepatic MC infiltration and large duct H2HR 
activation promotes liver inflammation, fibrosis and angiogenesis. Inhibition of MC 
activation or large duct H2HR signaling reduces these damaging effects. Blocking MCs 
or large cholangiocyte H2HR activity may be a therapeutic option for patients suffering 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
The Liver and Hepatic Cell Types 
The liver is a complex organ that regulates key functions necessary for maintaining 
cellular homeostasis. The liver plays important roles in detoxification, drug metabolism, 
lipid metabolism and bile acid synthesis/secretion (1). The liver is comprised of multiple 
cell types including hepatocytes, Kupffer cells (resident macrophages), hepatic stellate 
cells (HSCs), liver sinusoidal endothelial cells, biliary epithelial cells (cholangiocytes), and 
other resident and infiltrating cell types (1).  
Cholangiocytes 
Cholangiocytes are the epithelial cells that line the intrahepatic and extrahepatic 
ducts of the biliary tree and are the target of cholangiopathies, such as primary sclerosing 
cholangitis (PSC), primary biliary cholangitis (PBC) and cholangiocarcinoma (CCA).  
Cholangiocytes make up ~3-5% of the hepatic cell population, so while this cell type does 
not make up the majority of the liver, we and others have shown that cholangiocytes have 
key roles in the maintenance of hepatic homeostasis under normal conditions, and the 
promotion of disease progression following injury (2-4). Cholangiocytes are primarily 
known for their modification of bile composition and detoxification of xenobiotics, and 
during normal conditions they are mitotically dormant (5). During biliary-specific damage 
(i.e. cholangiopathies) cholangiocytes begin to proliferate and secrete a number of 
neuroendocrine factors that influence the surrounding microenvironment (2, 4, 5). In 
particular, biliary-derived vascular endothelial growth factor (VEGF)-A/C acts as a growth 
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promoting factor for the endothelial cells of the peribiliary vascular plexus (6). Similarly, 
other factors secreted from cholangiocytes, such as histamine, serotonin, substance P 
and neural growth factor (NGF) can act in both autocrine and paracrine manners to 
promote disease progression during cholestasis (7-12). 
Cholangiocytes are heterogenous and can be subcategorized as either small (<15 
µm diameter, line the small bile ducts) or large (³15 µm diameter, line the large bile ducts) 
cholangiocytes in rodents (2, 4). Not only do small and large cholangiocytes vary in size, 
but they vary in function and response to damage (3, 13, 14). It has been reported that 
large cholangiocytes are more susceptible to damage and become senescent, which has 
been hypothesized to promote disease progression during cholangiopathies (10-12, 15). 
Functionally, small cholangiocytes promote their proliferation through Ca2+-dependent 
mechanisms, whereas large cholangiocytes increase their proliferation via cyclic 
adenosine monophosphate (cAMP)/phosphorylated p44/42 mitogen-activated protein 
kinases (pERK) signaling (2, 7, 13, 15, 16). Further, we have demonstrated that small 
cholangiocytes express the H1 histamine receptor (H1HR), whereas large cholangiocytes 
express H2HR (7). It is interesting to note that Ca2+ signaling is downstream of H1HR, 
whereas H2HR activation leads to cAMP/pERK signaling, which mimics the functional 
signaling mechanisms that are known to promote small versus large cholangiocyte 
proliferation (2, 4, 7, 13, 16). Further, multidrug resistance-2 knockout (Mdr2-/-, a model 
of PSC) mice show a slight increase in H1HR expression primarily in small (minimally in 
large) cholangiocytes, but a significant increase in H2HR in large (but not small) 
cholangiocytes (15). Similarly, human PSC patients show increased biliary H1HR and 
H2HR expression; however, the expression of these HRs in human small versus large 
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ducts has not been demonstrated (15). PBC is characterized by ductopenia of the small 
ducts; therefore, one could assume that H1HR signaling may play a role in PBC 
progression. However, ~70% of PSC cases are characterized by large duct damage, 
which eludes to the role of H2HR signaling in this disease. In support of this, we have 
found that, in Mdr2-/- mice, where we see an increase in large H2HR expression, we 
subsequently see an increase in predominantly large duct mass (15). Therefore, we 
hypothesize that increased large duct H2HR expression and signaling promotes the 
progression of PSC. 
Proliferation of large ducts has been hypothesized to be supported by a stem cell 
niche found within the peribiliary glands (17, 18). The peribiliary glands contain serous 
and mucinous acini, as well as stem/progenitor cells, and reside near large ducts (17-19). 
The peribiliary glands are structurally and mechanistically different from hepatic 
progenitor cells, which are the stem/progenitor cell population that reside near and 
repopulate the small cholangiocyte population during specific injury (19). It has been 
demonstrated that the peribiliary glands become activated during cholestatic injury, 
including PSC, and may increase the proliferation of the stem/progenitor cells, as well as 
their differentiation into large cholangiocytes (17, 18).  
Kupffer Cells 
Kupffer cells are the tissue-resident macrophages in the liver that contain 
phagocytic capabilities but can mediate hepatic inflammation as well (20, 21). Kupffer 
cells, like other macrophages, maintain innate immunity within the liver through the 
phagocytosis of infectious materials and cellular debris (20). Kupffer cells reside within 
the sinusoids of the liver and have immediate surveillance of pathogens entering via the 
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portal venous system (22). Additionally, Kupffer cells can be activated by various factors 
to induce a strong inflammatory response (21). Activated Kupffer cells respond to, and 
secrete, various cytokines and chemokines that drive hepatic inflammation, especially in 
the setting of cholestasis (21, 23). During a pro-inflammatory state, Kupffer cells can 
release tumor necrosis factor (TNF)-a, interleukin (IL)-6, IL-1b and transforming growth 
factor (TGF)-b1 that promote liver damage (24, 25). Secretion of these and other factors 
from Kupffer cells allows paracrine interactions with nearby cells to mediate their 
response. For instance, Kupffer cells can communicate with HSCs (also located in the 
hepatic sinusoids) during liver injury to induce HSC activation (26, 27). Kupffer cells also 
signal to hepatocytes to influence disease progression following liver damage (28, 29); 
however, signaling between Kupffer cells and cholangiocytes has yet to be elucidated. 
Furthermore, Kupffer cells can influence the infiltration of other cells, such as neutrophils 
(30), so they may have an unknown impact on MC migration and activation. 
Hepatic Stellate Cells (HSCs) 
Hepatic fibrosis is characterized by the accumulation of extracellular matrix (ECM) 
and is the byproduct of chronic liver injury including cholestasis (31). ECM deposition 
during liver injury is mediated by myofibroblasts, which can arise from activated HSCs or 
portal fibroblasts, but HSC activation contributes to collagen deposition and liver fibrosis 
to a greater degree than activated portal fibroblasts (32). In a normal state, HSCs are 
quiescent and store vitamin A, but following injury they transdifferentiate into 
myofibroblasts that contain contractile, inflammatory and fibrogenic properties (33). The 
initiation of HSCs is defined by the activation of this cell type by specific factors, secreted 
from nearby cells, causing HSCs to increase their expression of growth factor receptors 
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and fibrogenic response. Perpetuation of these events amplifies activated HSC 
phenotypes, thus pushing them to a myofibroblast state (34). TGF-b1 is one of the most 
potent activators of HSCs (35), and HSC activation can be mediated by various cell types, 
including cholangiocytes (11, 12). Specifically, cholangiocyte-derived TGF-b1 and 
senescence-associated secretory phenotypes (SASPs) have been shown to promote 
HSC activation and liver fibrosis during models of cholestasis (11, 12). There is a 
correlation between increased MC infiltration and HSC activation/fibrogenesis exhibited 
in models of cholestasis (15, 36, 37); therefore, infiltrating and activated MCs may play a 
role in HSC activation and ECM remodeling. 
Endothelial Cells 
The liver has its own well-defined vasculature that is crucial for development, 
tissue growth and regeneration (38). Angiogenesis is the formation of new vessels from 
the existing vasculature and can occur within the liver during growth and repair (39). 
Angiogenesis has a key role in physiology, but can influence pathology as well. In 
particular, angiogenesis has been shown to contribute to inflammatory and fibrogenic 
responses during chronic liver disease (40-42). During chronic liver injury, persistent 
inflammation causes increased vascular permeability and promotes the recruitment of 
immune and inflammatory cells (43, 44), which may include MCs. In turn, these infiltrating 
cells can secrete cytokines and growth factors that further promote endothelial cell 
proliferation and migration (45, 46). During the angiogenic process, ECM remodeling is 
necessary for new sprout formation (47, 48). ECM remodeling is also a key process for 
the progression of liver fibrosis, indicating that these two activities are closely intertwined. 
Several angiogenic factors, including VEGF, fibroblast growth factor (FGF) and 
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angiopoietin (Ang)-1 induce endothelial cell proliferation and tube formation, thereby 
promoting angiogenesis (49, 50), and these factors can be derived from cholangiocytes, 
as well as from MCs (6, 51, 52). The biliary tree has its own vascular network termed the 
peribiliary vascular plexus, which resides in close proximity to large bile ducts (53). It has 
been nicely demonstrated that the blood supply from the peribiliary vascular plexus 
nourishes the biliary tree during growth, but in turn growth factors secreted by 
cholangiocytes support the peribiliary vascular plexus (6, 54). In addition, Kupffer cells 
and HSCs may play a prominent role in angiogenesis during injury (55, 56). It is evident 
that there are complex signaling mechanisms and cellular interactions that occur during 
the progression of liver disease to influence biliary damage, inflammation, liver fibrosis 
and angiogenesis. 
 
Human Cholestatic Liver Diseases 
Cholestasis is generally characterized by the impairment of bile flow, causing 
accumulation of toxic bile acids in the liver (57, 58). Normal bile physiology is dependent 
on various membrane transporters and nuclear receptors found on hepatocytes as well 
as cholangiocytes (59, 60). Mutations in various bile acid transporters has been linked to 
increased susceptibility of developing various cholestatic diseases; specifically, MDR3 
mutations have been linked to PSC, ABCB11 mutations in progressive familial 
intrahepatic cholestasis, and more recently SLC51B mutations in the development of 
congenital diarrhea coupled with cholestasis (61, 62). However, there may be other 
factors mediating disease onset and progression, such as infection, gut dysbiosis, 
improper immune response and environmental factors (63, 64). 
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Cholestatic diseases targeting the cholangiocytes (i.e. cholangiopathies) are 
progressive diseases leading to end-stage liver disease with few to no therapeutic options 
(64, 65). PBC and PSC are two of the main cholangiopathies, accounting for 
approximately two-thirds of patients referred for liver transplantation (66). In fact, 
approximately 16% of liver transplants performed in the United States between 1988 and 
2014 were for cholangiopathies (63). It is apparent that the treatment of cholangiopathies 
remains a significant problem; therefore, understanding mechanisms of disease 
progression may lead to better therapeutics for patients. 
Primary Biliary Cholangitis 
PBC is a chronic, cholestatic liver disease characterized by inflammation, bridging 
fibrosis and ductopenia at later stages, and may progress to cirrhosis during end-stage 
disease (63, 67). The prevalence of PBC is approximately 40 per 100,000 people, but 
these rates have gradually risen over time, according to a 2012 study (68). It is interesting 
to note that approximately 90% of PBC patients are female, with the average age of 
diagnosis being 55 years (69). Patients are diagnosed with PBC by having more than 
twice the upper limit of normal alkaline phosphatase (ALP) serum levels, alongside 
positive serum antimitochondrial antibodies (70). Ursodeoxycholic acid (UDCA) was the 
first FDA-approved therapy for the treatment of PBC, but 30-40% of patients fail to 
respond to this treatment (67). Obeticholic acid (OCA) was the second FDA-approved 
treatment for PBC, specifically for patients that were unresponsive or intolerant to UDCA, 
but only around 50% of patients showed significant reductions in serum ALP following 
OCA treatment (67, 71). As well, long-term outcomes of OCA treatment, such as rates 
for liver transplantation and mortality, are unknown (67, 71). While PBC is considered an 
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autoimmune disease, patients do not respond to typical immunosuppressive agents, 
making the treatment for this disease even more complicated (72). 
Primary Sclerosing Cholangitis 
PSC is characterized by chronic, peribiliary inflammation and fibrosis that can lead 
to stricturing of the ducts (obstructive cholestasis), and eventual cirrhosis and end-stage 
disease (63, 73). The prevalence of PSC varies greatly, from 0 – 16.2 per 100,000 people, 
but similar to PBC the prevalence of PSC is on the rise (68). PSC is primarily diagnosed 
in males, with the average age of diagnosis being 30 – 40 years (73). Of interest, 
approximately 70% of patients diagnosed with PSC also present with some form of 
inflammatory bowel disease, typically ulcerative colitis, further underlining the 
inflammatory component of this disease (74). PSC is diagnosed by having serum ALP 
levels twice the upper limit of normal, cholangiographic evidence of biliary stricturing and 
the exclusion of secondary sclerosing cholangitis (73, 74). The majority of PSC cases are 
found to affect only the large ducts of the biliary tree, but there is a small portion of PSC 
cases that show damage to the small ducts (75), and it is currently unknown why certain 
portions of the biliary tree are affected in different cases. It is also important to note that 
CCA is found in conjunction with PSC in 20 – 30% of diagnoses, and in 50% of cases 1 
year after diagnosis (76). Currently, there are no effective therapies for the treatment of 
PSC, with liver transplantation being the only treatment option (63); however, recurrence 







MCs were first characterized by Dr. Paul Ehrlich in 1878 (78). MCs are an immune 
cell type largely known for their mediation of allergies and inflammation; however, their 
role in autoimmune, infectious and other disorders is becoming more known (78-82). MCs 
originate from CD34+ hematopoietic stem cells following stimulation with stem cell factor 
(SCF) and ILs, which mediate the development of different MC subtypes (82). Upon 
leaving the bone marrow, MCs circulate throughout the body via the lymphatic and 
vascular systems and migrate towards damaged tissues where they complete their 
development, which is determined by the local microenvironment (83). MCs can be found 
throughout the body but are preferentially located in connective tissue and in mucosal 
sites (78-80). MC distribution and final location is dependent on constitutive homing, 
factors initiating recruitment, MC survival and local maturation (84, 85).  
As stated, MCs finish their maturation once they reach their final destination; 
therefore, their receptor expression and secretion of factors vary greatly depending on 
the microenvironment (78, 79, 84). In humans, MCs are categorized based on their 
protease expression: MCT for tryptase, and MCTC for tryptase and chymase (86, 87). MCT 
are generally found in mucosal sites, while MCTC are mostly found in connective tissues 
(88, 89). Similarly, in rodents, the MC subpopulations are divided into connective tissue-
type MCs (CTMCs) and mucosal-type MCs (MMCs) (88, 90). These two rodent 
populations can be distinguished by their specific markers; mast cell protease 1 (MCP-1) 
is found in CTMCs, while MCP-2 is found in MMCs (88, 91). In both humans and rodents, 
these different populations of MCs show different modes of activation and release of 
different molecules (92, 93), further cementing the concept of MC heterogeneity. 
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MCs express a plethora of surface markers, including FCeRI, complement 
receptors, HRs, toll-like receptors and serotonin receptors, which allows MCs to become 
activated by a number of factors (85). There are typical MC agonists that are known to 
promote MC migration; including, SCF, IgE, sphingosine-1-phosphate, histamine and 
various ILs and chemokines (15, 37, 88, 94); however, there are a number of non-
traditional chemoattractants that have been identified. Leptin has been found to stimulate 
MC migration and pro-inflammatory activation (95), which may have implications for non-
alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 
Additionally, plasminogen activator inhibitor type 1 (PAI-1) secreted from keratinocytes 
recruits MCs to the skin, which in turn promotes fibrogenesis (96). Considering that PAI-
1 is a senescence factor, and cholangiocytes become senescent during chronic liver 
injury, there may be a role of PAI-1 and other senescence factors for the migration and 
activation of MCs.  
Following migration and activation, MCs increase cytokine production and 
degranulate to release a variety of substances, including histamine, proteases, serotonin, 
TGF-b1 and VEGF (79). Specifically, MC release of IL-17A following activation results in 
increased tissue inflammation in the skin and gut (97). Interestingly, it has been shown 
that activated MCs release microvesicles that can promote endothelial cell cytokine 
expression in vitro (98). As well, hepatitis C virus infection upregulates MC microRNA 
(miR)-490 expression and exosomal secretion, which can be taken up by hepatocytes in 
vitro (99). Work from our group has demonstrated that inhibition of MC-derived histamine 
reduces cholestatic liver injury, including biliary damage, liver fibrosis, angiogenesis, bile 
flow and total bile acid levels (100). Additionally, we have found that inhibition of MC-
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derived TGF-b1 or farnesoid X receptor (FXR, nuclear receptor involved in bile acid 
synthesis) blocks cholestasis-induced liver injury (Kennedy, Meadows and Francis, 
unpublished observations, 2018). 
Within the liver, MCs are primarily found near hepatic arteries, veins and bile ducts 
(37, 100). In normal livers, MCs are found in small number in portal areas, but MC number 
increases following injury (100-102). Our data indicates that damaged cholangiocytes, 
but not hepatocytes or HSCs, release factors that promote MC infiltration and activation 
(Kennedy and Francis, unpublished observations, 2017). In particular, we have previously 
shown that during CCA (i.e. cancer of the bile ducts) there is increased secretion of SCF 
that promotes MC migration via interaction with the receptor c-Kit (94). As well, increased 
hepatic MC number has been noted in PBC and PSC patients (100, 103), and similar to 
CCA, patients with PSC have increased c-Kit-positive MC infiltration near bile ducts 
expressing increased SCF (102). Furthermore, it has been demonstrated that MC 
presence correlates with increased stage of fibrosis in NASH (104); therefore, inhibition 
of MC migration or activation may be a therapeutic option for a number of diseases. 
Specifically, we have shown that human CCA has increased MC infiltration, which 
is mediated by CCA-derived SCF binding to c-Kit on MCs (94). In rats subjected to bile 
duct ligation (BDL, a model of obstructive cholestasis), we note an increase in MC 
number, specifically in peribiliary areas, which increases over time and correlates with 
increased damage (37); an increase in MC number has also been shown in Mdr2-/- mice 
along with enhanced liver damage (100). However, treatment with cromolyn sodium 
(which inhibits MC degranulation and histamine release) in either BDL rats or Mdr2-/- mice 
reduces MC activation and subsequent liver damage (37, 100). Others have found that 
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MC-derived extracellular vesicles can be taken up by HSCs to promote their activation 
(105), further supporting the pro-fibrogenic role of MCs. Additionally, in the cholestatic 
model of carbon tetrachloride (CCl4) treatment, there was an accumulation of hepatic 
MCs that correlated with increased steatosis and inflammation, which was blocked by 
vitamin E treatment (106). These studies elude to the therapeutic potential of blocking 
MC migration or activation during various liver injuries. 
 
Models of Cholestasis 
During normal conditions, cholangiocytes are mitotically dormant; however, during 
cholestatic injury cholangiocytes become hyperplastic, express a neuroendocrine 
phenotype and subsequently release factors that can promote MC activation, as well as 
damage to nearby hepatic cells (12, 15, 107, 108). Particularly, we know that injured 
cholangiocytes secrete histamine, VEGF, substance P, and senescence factors that may 
be involved in MC chemoattraction (9, 11, 51, 109). One of the classic models of 
cholestasis is the BDL model of obstructive cholestasis. With this model, the common bile 
duct is ligated, to block bile flow and mimic obstructive cholestasis and induce a strong 
inflammatory and fibrogenic reaction, alongside biliary injury (8, 16, 109). BDL is an 
established model that we regularly use in our lab (2, 8, 16, 109, 110), and we have 
previously demonstrated that following BDL, cholangiocytes become hyperplastic and 
hepatic MC migration/activation is significantly increased, thereby promoting liver 
damage (36, 101). Since BDL induces biliary damage reminiscent of cholestatic injury, 
and promotes the migration and activation of MCs, this model is beneficial for the studies 
of MCs during cholestatic liver injury. 
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Another commonly used model of cholestasis is the Mdr2-/- mouse model of PSC 
(111). These mice are lacking the ATP-binding cassette, sub-family B, member 4 (i.e. 
Mdr2), so they are unable to secrete phospholipids into the bile, thus leading to liver injury, 
sclerosing cholangitis and cholelithiasis (112). Specifically, this model mimics some 
characteristics similar to human PSC; such as increased biliary proliferation, 
inflammation, and peribiliary fibrosis, and these phenotypes further increase over time 
(15, 111). Since PSC patients show similar liver phenotypes, and since there is evidence 
for mutation of the MDR3 gene (human ortholog of Mdr2), this model is ideal for the study 
of PSC (112). We have demonstrated that Mdr2-/- mice have increased MC number (15, 
100), which increases over time and corresponds with increased disease progression 
(Kennedy and Francis, unpublished observations, 2018). Similar to the BDL model, the 
Mdr2-/- mouse is a useful tool for the study of cholestatic liver injury, specifically PSC, and 
MC promotion of this disease. 
 
Histamine Signaling  
Histamine is a biogenic amine that was first isolated and characterized in 1910 by 
Sir Henry Dale, who found that it had a stimulating effect on smooth muscle from the gut 
and the respiratory tract (113). Since then, histamine has largely been recognized for its 
modulation of inflammatory and allergic responses (114); however, the role of histamine 
in pathological responses is becoming more recognized.  
Histamine is synthesized from the amino acid histidine by the enzyme L-histidine 
decarboxylase (HDC) (115, 116). Histamine synthesis increases in growing tissues (117); 
as well, studies have shown that HDC expression is increased in neuroendocrine tumors 
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and multiple malignant cell lines (15, 115, 118). Additionally, in adult animals the liver 
contains one of the highest concentrations of HDC (119). We have found that 
cholangiocytes have the highest expression of HDC and secretion of histamine when 
compared to other liver cell types, and these parameters are further increased following 
damage (109). Aside from histamine synthesis, HDC is able to regulate cholangiocyte 
proliferation by increasing VEGF expression and secretion via pERK signaling (109). 
Histamine can signal through one of its four G protein-coupled receptors (H1-H4 
HRs), and our lab has demonstrated that H1 and H2 HR activation increases, whereas 
H3 and H4 HR activation decreases, cholangiocyte proliferation (7, 16, 120). Specifically, 
H1HR acts via Gaq, mobilizing Ca2+, whereas H2HR signals through Gas, coupling to 
cAMP, and subsequent pERK activation (121, 122). Conversely, H3 and H4 HR activation 
decreases cAMP accumulation (123, 124). As previously stated, there is a prominent 
increase in large cholangiocyte H2HR expression in conjunction with increased biliary 
proliferation. In this same manuscript, we demonstrated that treatment with the H2HR 
antagonist, ranitidine, brought about a significant reduction in large duct mass along with 
decreased liver fibrosis (15). Since (i) PSC primarily affects the large ducts, (ii) H2HR is 
preferentially expressed on large cholangiocytes, (iii) activated MCs secrete large 
amounts of histamine, and (iv) infiltrating MCs reside in close proximity to large ducts, the 
aim of this study was to evaluate the impact of MC-derived histamine on large 








Reagents and Materials 
Reagents were purchased from Sigma Aldrich Co. (St. Louis, MO) unless 
otherwise indicated. Reagents for cell culture were obtained from Invitrogen Corporation 
(Carlsbad, CA). Total RNA was isolated from total liver, freshly isolated cells and cultured 
cells using the TRI Reagent from Sigma Life Science and was reverse transcribed with 
the Reaction Ready First Strand cDNA Synthesis kit (Qiagen, Valencia, CA).  
 
Animal Models 
We utilized commercially available homozygous mast cell-deficient C57BL/6J-KitW-
sh/J (KitW-sh) mice obtained from Jackson Laboratory (Sacramento, CA) along with age-
matched wild-type (WT) mice. Pair breeding was utilized to generate offspring and only 
male mice were used in our study. WT and KitW-sh mice (at least 12 weeks of age) were 
subjected to sham or BDL (as described (8, 110)) for up to 7 days and, in separate 
experiments, KitW-sh mice (at least 8 weeks of age) were injected with sterile, cultured 
MCs (MC/9 (ATCC® CRL-8306™)) or MC medium (control) prior to sacrifice 3 days 
later. At least 8-10 mice were used for each experimental group. Cultured MCs were 
tagged with PKH26 Red Fluorescent Cell Linker prior to injection and mice received a 
                                               
*Part of this chapter is reprinted with permission from “Bile Duct Ligation-Induced Biliary Hyperplasia, Hepatic Injury, and Fibrosis 
Are Reduced in Mast Cell-Deficient KitW-sh Mice” by Hargrove L, Kennedy L, Demieville J, Jones H, Meng F, DeMorrow S, Karstens 
W, Madeka T, Greene J Jr, Francis H, 2017. Hepatology, 65, 1991-2004, Copyright 2017 by John Wiley and Sons. 
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single injection of sterile, cultured MCs (5×106 cells in 0.1 ml sterile MC medium) or 
vehicle control via tail vein injection (125). Following euthanasia, the location of injected 
MCs was determined using confocal microscopy for the visualization of PKH26 Red 
Fluorescent Cell Linker. Livers were co-stained with CK-19 to mark bile ducts and aid in 
the location of injected MCs. 
For a separate set of animal studies, we used the multidrug resistant genetically 
modified mouse model of PSC, Mdr2-/- mice raised on FVB/NJ background (wild-type, 
WT) (111). Male WT and Mdr2-/- mice were treated with either mismatch morpholino 
(TAAACCATGCAATTGGACTCAATTC) or an H2HR-specific Vivo Morpholino 
(TGAACCGTGCCATTGGGCTCCATTC) given by tail vein injection 2x/week for 1 week 
(4 µg/100 µl NaCl). Mice (8-10 per group) were euthanized at 8 and 12 weeks of age, 
times at which they display an increase in PSC-induced hepatic damage (15, 111).  
All mice were housed in the Baylor Scott and White Health Animal Facility and 
given free access to drinking water and standard chow. Animals were kept in a 
temperature-controlled environment with a 12:12 hr light/dark cycle, and all protocols 
were approved by and strictly adhered to regulations set forth by the local IACUC 
committee. From all animals we collected serum, liver samples and isolated 
cholangiocytes. Cholangiocyte supernatants were collected and incubated at 37°C for up 
to 6 hours (37).  
 
Analysis of Liver Damage 
H&E staining was performed in liver sections to evaluate lobular damage, necrosis 
and inflammation. H&E staining was evaluated by a board-certified pathologist in a 
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blinded manner. Serum levels of alanine transaminase (ALT) and gamma-glutamyl 
transferase (g-GT) were evaluated in certain groups of mice using the IDEXX Catalyst 
One test slides (IDEXX, Westbrook, ME). 
 
Assessment of MC Presence and the Histamine/HR Axis 
MC localization was assessed by immunohistochemistry for mouse mast cell 
protease-1 (mMCP-1) in liver sections, and gene expression of c-Kit, chymase and 
tryptase (MC markers) was measured in total liver by quantitative real-time PCR (qPCR). 
Histamine secretion was evaluated by EIA in serum from all groups using the Histamine 
EIA Kit (Cayman Chemical; Ann Arbor, MI). Expression levels of H1HR and H2HR were 
measured by immunohistochemistry or immunofluorescence (co-stained with CK-19 to 
label bile ducts) in liver sections. 
 
Measurement of IBDM and Cholangiocyte Proliferation 
Since increased intrahepatic bile duct mass (IBDM, indicative of ductular reaction) 
and cholangiocyte proliferation are found in BDL and Mdr2-/- mice, we evaluated these 
parameters in our models by immunohistochemistry with semi-quantification of CK-19 
(13, 15). To further define whether MC presence modifies small or large bile duct mass, 
we again performed immunohistochemistry for CK-19 in liver sections and categorized 
bile duct mass into small (<14 µm diameter) or large (³14 µm diameter) ducts in our BDL 
studies and MC injection models. We have previously demonstrated that stimulation of 
H2HR enhances large, but not small, IBDM (15); therefore, we measured changes in 
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large IBDM in Mdr2-/- mice that were injected with H2HR Vivo Morpholino or mismatch 
controls. 
 
Evaluation of Kupffer Cell Number, HSC Activation, Hepatic Fibrosis and 
Angiogenesis 
Increased Kupffer cell presence has been noted in various models of cholestasis, 
as well as in humans with cholestatic injury (23, 126). To evaluate changes in Kupffer cell 
number, liver sections were stained for F4/80 (Kupffer cell marker). 
HSCs are the key contributors to hepatic fibrosis during liver injury, and increased 
HSC number has been seen in a number of cholestatic injury models (11, 27, 32, 36). To 
evaluate if MC presence correlates with increased HSC number and activation, we 
performed immunofluorescence in liver sections for desmin (HSC marker) co-stained for 
CK-19 (to image bile ducts). To investigate if blocking H2HR signaling alters HSC 
activation, we again visualized the expression of synaptophysin-9 (SYP-9, marker of 
activated HSCs) by immunofluorescence, co-stained for CK-19. To determine changes in 
liver fibrosis, that are mediated by HSCs, we performed staining in liver sections using 
Masson’s Trichrome and Sirius Red (semi-quantified), and qPCR for a-SMA, fibronectin-
1 (FN-1) and collagen type-1a in total liver RNA. 
TGF-b1 is a strong regulator of HSC activation and hepatic fibrosis. We measured 
TGF-b1 signaling in our models by (i) hepatic and isolated large cholangiocyte expression 
by qPCR, (ii) hepatic expression by immunofluorescence (co-stained for CK-19 to image 
bile ducts) and (iii) secretion in serum by EIA. 
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Vascular remodeling was visualized in our models by immunofluorescence for von 
Willebrand factor (vWF) and CK-19 (to image bile ducts). As well, the gene expression of 
vWF was determined in total liver RNA by qPCR. VEGF-C expression in isolated large 
cholangiocytes was verified by qPCR. Expression and secretion of VEGF-A in large 
cholangiocyte supernatants was determined by qPCR and EIA, respectively. 
 
Visualization of Intracellular Signaling 
Our previous work has shown that H2HR signals primarily through activation of 
Gas/cAMP/pERK; therefore, we evaluated this signaling pathway in our mouse models. 
Intracellular cAMP and pERK expression were determined by immunofluorescence (co-
stained with CK-19 to visualize localization within bile ducts). These results were 
evaluated for changes in small versus large bile ducts based on bile duct diameter as 
described above. 
 
In Vitro Methods 
Since we have found that MCs primarily reside near large ducts, we wanted to 
investigate whether damaged cholangiocytes (small versus large) induced the migration 
of MCs in vitro. For these studies, we utilized our immortalized, large mouse 
cholangiocyte cell lines and immortalized, small mouse cholangiocyte cell lines that were 
generated by SV-40 transformation and previously used by us (3), as well as a fetal 
mouse liver MC line (MC/9, ATCC) also previously used by us (15, 36). Immortalized 
small and large cholangiocytes were treated with of lipopolysaccharide (LPS, 100 ng/mL) 
for 24 hrs (to induce damage) prior to being placed in the bottom well of Boyden 
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chambers; the top well was loaded with cultured MCs and migration through transwell 
membranes was assessed 24 hrs later by counting toluidine blue-positive cells (94). 
We have previously demonstrated that H2HR expression is primarily in large 
cholangiocytes (15); therefore, we wanted to evaluate the impact of MC-derived histamine 
on large cholangiocyte proliferation and damage. We performed all in vitro studies using 
our immortalized, large mouse cholangiocyte cell lines and our cultured MC cell line. In 
vitro, MCs were treated with either 0.1% BSA (control) or an HDC inhibitor (3 mM, a-
methyl-DL-histidine (a-Me)) for 48 hrs. Large cholangiocytes were treated with 
supernatants from treated MCs and were evaluated for (i) proliferation by Ki67 staining, 
(ii) senescence by p18 immunofluorescent staining, and (iii) H2HR/pERK signaling by 
immunofluorescent staining. 
Lastly, we wanted to demonstrate that large cholangiocytes treated with MC 
supernatants were acting through cAMP signaling. In vitro, large cholangiocytes were 
treated with supernatants from control- or a-Me-treated MCs, and were assessed for 




All data is expressed as mean ± standard error of the mean (SEM). Groups were 
analyzed by the Student unpaired t test when two groups are analyzed or a two-way 
ANOVA when more than two groups are analyzed, followed by an appropriate post hoc 







Injected MCs are Found in Close Proximity to Bile Ducts 
We first verified that our injection model was able to efficiently deliver MCs to the 
liver. We found few injected MCs in the lung and spleen; however, injected MCs were 




Figure 1, MC Localization Following Tail Vein Injection.   MC localization following tail vein injection was 
determined in Kit
W-sh
 mice. Confocal imaging for PKH26 (red) in the lungs, spleens and livers from Kit
W-sh
 
mice injected with sterile PKH26-tagged MCs reveals that the majority of injected MCs (white arrows) are 
in the liver and not found in lung or spleen. Livers were co-stained with CK-19 (green) to mark bile ducts 
for MC localization. Images are 20× magnification. 
                                               
*Part of this chapter is reprinted with permission from “Bile Duct Ligation-Induced Biliary Hyperplasia, Hepatic Injury, and Fibrosis 
Are Reduced in Mast Cell-Deficient KitW-sh Mice” by Hargrove L, Kennedy L, Demieville J, Jones H, Meng F, DeMorrow S, Karstens 
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Hepatic Injury is Ameliorated in BDL KitW-sh Mice  
BDL WT mice displayed increased focal necrosis (infarct) in zone 2 (upwards of 
4–5% of lobule) and portal inflammatory changes that are consistent with obstruction 
(Figure 2A, indicated by black arrowheads). An increase in mostly large bile ducts is also 
observed following BDL (indicated by black arrows) in WT mice. In BDL KitW-sh mice the 
degree of focal necrosis (infarct) was zero compared to BDL WT mice. ALT activity was 
significantly upregulated in BDL WT mice, but this increase was completely abolished in 
the BDL KitW-sh mice, which demonstrated ALT levels similar to those in sham WT mice 
(Figure 2B). These findings support previously reported findings that BDL primarily 
induces large duct damage, which is ameliorated when MCs are absent.  
 
MC Injection Does Not Recapitulate BDL-Induced Hepatic Injury in KitW-sh 
Mice 
To evaluate whether MC injections recapitulate BDL-induced damage, we re-
injected MCs into MC-deficient (KitW-sh) mice and evaluated the same parameters. In the 
livers of KitW-sh mice injected with MCs there were no visible areas of liver infarcts/focal 
necrosis or portal inflammation/damage compared to KitW-sh mice injected with PBS 
(Figure 2C). Further, ALT levels were not significantly altered after MC injection compared 







Figure 2, Analysis of Liver Damage.   Liver damage was assessed by H&E staining of liver sections from 
all groups. BDL WT mice had increased focal necrosis (infarct) indicated by black arrowheads (upwards of 
4–5% of lobule) and portal inflammatory changes that are consistent with obstruction. An increase in mostly 
large bile ducts is observed following BDL (indicated by black arrows). In Kit
W-sh
 sham mice and Kit
W-sh
 mice 
subjected to BDL, necrosis/liver infarcts were absent (A). ALT activity was increased in BDL WT compared 
to sham WT, whereas ALT activity in both sham and BDL Kit
W-sh
 sham mice was similar to sham WT 
(B). Kit
W-sh
 mice injected with MCs had no visible areas of liver necrosis/infarcts or portal 
inflammation/damage compared to Kit
W-sh
 mice injected with control (C) and ALT levels were unchanged 
(D). Data are expressed as mean ± SEM of at least 6 experiments for ALT. *p<0.05 versus sham WT mice; 




IBDM and Cholangiocyte Proliferation are Significantly Reduced in BDL 
KitW-sh Mice 
In line with our previous publications, BDL WT mice had an increase in IBDM 
compared to sham WT mice. However, in BDL KitW-sh mice there is an overall reduction 
in IBDM compared to BDL WT mice (Figure 3A). These results were further confirmed by 



































demonstrating a similar trend to that noted in the immunohistochemistry results. As 
expected, biliary proliferation (indicated by red arrows), evaluated by Ki-67 staining, was 
significantly decreased in BDL KitW-sh mice compared to BDL WT (Figure 4). However, 
cholangiocyte proliferation was similar between sham WT and KitW-sh mice (Figure 4). 





Figure 3, Evaluation of IBDM Following BDL.   IBDM (A and B) was evaluated in liver sections from WT 
and Kit
W-sh
 subjected to sham and BDL surgery. We found that IBDM (assessed by CK-19 staining (A), 
western blotting (B) and qPCR (C)) increased in BDL WT mice when compared to sham WT mice, whereas 
IBDM was reduced in BDL Kit
W-sh
 mice. Semi-quantitative data is expressed as mean ± SEM of at least 10 
experiments for CK-19, at least 8 experiments for western blotting and 4 experiments for qPCR. *p<0.05 

































































Figure 4, Assessment of Cholangiocyte Proliferation Following BDL.   Cholangiocyte proliferation was 
evaluated in liver sections from WT and Kit
W-sh
 subjected to sham and BDL surgery. We found that 
cholangiocyte proliferation (red arrows), as indicated by Ki-67 staining, increased in BDL WT mice when 
compared to sham WT mice, whereas the number of proliferating cholangiocytes was reduced in BDL Kit
W-
sh
 mice. Semi-quantitative data are expressed as mean ± SEM of at least 10 experiments. *p<0.05 versus 
sham WT mice; #p<0.05 versus BDL WT mice. Images are 20× magnification. 
 
 
MC Injection Increases IBDM and Cholangiocyte Proliferation in KitW-sh Mice 
When looking at our MC injection models, we found that KitW-sh mice injected with 
MCs had a significant increase in IBDM when compared to KitW-sh mice (Figure 5A). 
Similarly, cholangiocyte proliferation was increased in KitW-sh mice injected with MCs 
when compared to controls (Figure 5B). CK-19 expression was further confirmed by 








































Figure 5, Evaluation of IBDM and Cholangiocyte Proliferation Following MC Injection.   Evaluation of 
IBDM and proliferation following the MC injection into Kit
W-sh
 mice. (A) IBDM and (B) biliary proliferation are 
increased in Kit
W-sh
 mice injected with MCs compared to control injections as shown by CK-19 (marked by 
black arrows) and Ki67 (marked by red arrows). Kit
W-sh 
mice injected with MCs have an increase in CK-19 
gene expression compared to mice injected with vehicle (C) that was confirmed by western blotting (D). 
Data are expressed as mean ± SEM of 10 experiments for CK-19, 4 experiments for qPCR and 8 
experiments for western blotting. *p<0.05 versus Kit
W-sh
 mice. Images are 20× magnification. 
 
 
MCs Influence Large, But Not Small, IBDM During BDL and Following MC 
Injection into KitW-sh Mice 
As previously stated, BDL induces the proliferation of large, but not small, 
cholangiocytes, thereby increasing large duct mass. When evaluating the differential 
impact of MCs on small versus large duct mass, we found that BDL KitW-sh mice had a 
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significant reduction in large IBDM when compared to BDL WT mice; however, there was 
a slight but significant increase in small IBDM in BDL KitW-sh mice as compared to sham 
KitW-sh mice (Figure 6). Interestingly, we noted that sham KitW-sh mice had a reduction in 
large IBDM, but an increase in small IBDM, when compared to sham WT mice (Figure 6). 
These findings suggest that MC presence mediates large cholangiocyte proliferation, and 
loss of MCs leads to a reduction in large cholangiocyte growth with an increase in small 





Figure 6, Determination of Small and Large IBDM Following BDL.   Small and large IBDM was 
determined in liver sections from WT and Kit
W-sh
 mice subjected to sham and BDL surgery. By CK-19 
staining, we noted that large (but not small) IBDM was increased in BDL WT mice when compared to sham 
WT mice; however, large IBDM was reduced in BDL Kit
W-sh
 mice when compared to BDL WT mice, with a 
compensatory increase in small duct mass when compared to sham Kit
W-sh
 mice. Interestingly, sham Kit
W-
sh
 mice had a significant increase in small duct mass, with a significant decrease in large duct mass, when 
compared to sham WT mice. Semi-quantitative data is expressed as mean ± SEM of at least 10 
experiments for CK-19. *p<0.05 versus sham WT mice; #p<0.05 versus BDL WT mice; &p<0.05 versus 
sham Kit
W-sh
 mice. Images are 10× magnification. 
 
 
Interestingly, we found that the injection of MCs into WT mice did not significantly 







































increase large IBDM with a slight increase in small IBDM; however, the change in small 
duct mass was not as prominent as the change in large duct mass (Figure 7). Therefore, 
we propose that MCs primarily target large cholangiocyte proliferation during models of 
cholestasis. Additionally, since MC injection modified large duct mass in KitW-sh mice, but 





Figure 7, Measurement of Small and Large Cholangiocyte Proliferation Following MC Injection.   
Small and large IBDM was evaluated in liver sections from MC injection mice. By CK-19 staining, we found 
that WT mice injected with MCs had no significant change in small or large IBDM when compared to WT 
mice injected with control. Similarly, the injection of MCs into Kit
W-sh
 mice increased both small and large 
IBDM, with a more prominent increase in large duct mass, when compared to Kit
W-sh
 mice injected with 
control. Semi-quantitative data is expressed as mean ± SEM of 10 experiments for CK-19. *p<0.05 versus 
WT mice; &p<0.05 versus Kit
W-sh
 mice. Images are 20× magnification. 
 
 
MCs Increase Kupffer Cell Number During BDL and Following MC Injection 
into KitW-sh Mice 
Kupffer cell number is increased in BDL and Mdr2-/- mice (23, 126). Using F4/80 
staining, we found that BDL KitW-sh mice had a significant reduction in Kupffer cell number 


























WT and KitW-sh mice subjected to sham operation (Figure 8). However, MC injection into 




Figure 8, Visualization of Kupffer Cell Number Following BDL or MC Injection.   Kupffer cell number 
was assessed by staining for F4/80 (Kupffer cell marker) in liver sections. We found that BDL WT mice had 
an increase in Kupffer cell number when compared to sham WT mice; however, BDL Kit
W-sh
 mice had a 
decrease in Kupffer cell number when compared to BDL WT mice. The injection of MCs into Kit
W-sh
 mice 
increased Kupffer cell number when compared to control injected Kit
W-sh




Hepatic Fibrosis and HSC Activation Are Dependent on MCs 
Collagen deposition is dramatically reduced in BDL KitW-sh mice compared to BDL 
WT mice as shown by Masson’s Trichrome and Sirius Red staining (Figure 9A and B). 
Semi-quantification of Sirius Red staining shows a significant decrease in collagen 
deposition in BDL KitW-sh mice compared to BDL WT mice (Figure 9C). Hydroxyproline 
content was significantly reduced in BDL KitW-sh mice compared to BDL WT mice (Figure 
9D). The expression of α-SMA, fibronectin-1 and collagen type-1a increased in BDL WT 
F4/80
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mice compared to sham WT mice; whereas, these markers were decreased in BDL KitW-




Figure 9, Evaluation of Hepatic Fibrosis Following BDL.   Fibrosis was evaluated by staining in WT 
and Kit
W-sh
 mice subjected to sham or BDL surgery. (A) Masson’s Trichrome and (B) Sirius Red staining 
show an increase in collagen deposition in BDL WT mice compared to sham WT mice, whereas collagen 
deposition is reduced in BDL Kit
W-sh
 mice compared to BDL WT mice. (C) The Sirius Red findings were 
quantified and presented as percent collagen deposition. (D) Hydroxyproline content in total liver was 
significantly increased in BDL WT mice compared to sham WT mice, but this was reduced in BDL Kit
W-
sh
 mice compared to BDL WT mice. Data are expressed as mean ± SEM of 6 experiments for hydroxyproline 
content and 10 images for Sirius Red. *p<0.05 versus sham WT mice; #p<0.05 versus BDL WT mice. 
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Figure 10, Expression of Fibrosis Genes Following BDL.   Evaluation of fibrotic marker gene expression 
in WT and Kit
W-sh
 mice subjected to sham or BDL surgery. Expression of collagen type-1a, !-SMA, and 
fibronectin-1 (FN-1) genes were measured by qPCR and all three were upregulated in BDL WT mice 
compared to sham WT mice. These fibrosis markers were decreased in BDL Kit
W-sh
 mice compared to BDL 
WT mice. Data are expressed as mean ± SEM of at least 9 experiments for real-time PCR. *p<0.05 versus 





TGF-b1 is a key promoter of liver fibrosis via HSC activation; therefore, we 
measured both of these parameters in our models. In BDL KitW-sh mice, there was a 
significant reduction in both TGF-β1 expression (Figure 11A) and secretion (Figure 11B) 
compared to BDL WT mice. Similarly, the number of HSCs, as demonstrated by desmin 
(HSC marker) expression, was increased in BDL WT mice, but reduced in BDL KitW-



































































Figure 11, Assessment of TGF-b1 Levels Following BDL.   Measurement of TGF-β1 expression in WT 
and Kit
W-sh 
mice subjected to sham or BDL surgery. (A) TGF-β1 gene expression and (B) secretion are 
increased in BDL WT mice compared to sham WT mice, whereas both expression and secretion of TGF-
β1 are decreased in BDL Kit
W-sh 
mice compared to BDL WT mice. (C) Data are expressed as mean ± SEM 
of 6 experiments for qPCR and at least 3 experiments run in triplicates for EIA. *p<0.05 versus sham WT 







Figure 12, Visualization of HSC Activation Following BDL.   Visualization of HSC activation assessed 
using desmin expression in WT and Kit
W-sh 
mice subjected to sham or BDL surgery. The number of desmin-
positive HSCs (stained green) was increased in BDL WT mice when compared to sham WT mice, but this 
was reduced in BDL Kit
W-sh
 mice when compared to BDL WT mice. Images are 40× magnification. 
 
 
It has been demonstrated that blocking MC activation reduces hepatic fibrosis and 
HSC activation in Mdr2-/- mice (15, 37, 100). We next evaluated if injection of MCs is able 






























































increased collagen deposition (Figure 13) and HSC activation (Figure 14) when compared 
to vehicle-injected mice. 
 
 
Figure 13, Determination of Liver Fibrosis and TGF-b1 Levels Following MC Injection.   Measurement 
of liver fibrosis following the reintroduction of MCs into MC-deficient, Kit
W-sh
 mice. (A) Masson’s Trichrome 
staining reveals an increase in collagen deposition in Kit
W-sh
 mice injected with MCs compared to 1X PBS. 
(B) Gene expression of fibrotic markers (collagen type-1a and fibronectin-1) are increased in Kit
W-sh
 mice 
injected with MCs compared to control injections and (C) hydroxyproline content is increased following 
injection with MCs compared to control. (D) TGF-β1 expression and secretion are upregulated in Kit
W-
sh
 mice injected with MCs compared to control injections. Data are expressed as mean ± SEM of at least 6 
experiments for qPCR and at least 3 experiments run in triplicate for EIA. *p<0.05 versus Kit
W-sh 
mice 































































































Figure 14, Visualization of HSC Activation Following MC Injection.   Visualization of HSC activation by 
desmin expression in following MC injection into Kit
W-sh 
mice. The number desmin-positive HSCs was 
increased in Kit
W-sh





Histamine Signaling and Secretion Are Decreased in BDL KitW-sh Mice 
In BDL WT mice, there was increased serum histamine levels alongside increased 
hepatic H1 and H2 HR gene expression when compared to sham WT mice; however, in 














Figure 15, Measurement of Histamine Secretion and H1/H2 HR Expression Following BDL.   
Measurement of histamine secretion and H1/H2 HR expression in WT and Kit
W-sh
 mice subjected to sham 
or BDL surgery. (A) Histamine secretion is upregulated in serum from BDL WT mice compared to sham 
WT mice, whereas histamine secretion from BDL Kit
W-sh
 mice serum is significantly decreased compared 
to BDL WT mouse serum. (B) H1 and H2 HR gene expression is increased in BDL WT mice compared to 
sham WT mice, whereas gene expression of H1 and H2 HR are decreased in BDL Kit
W-sh
 mice compared 
to BDL WT. Data are expressed as mean ± SEM of 3 experiments run in triplicate for EIA and 6 experiments 
for qPCR. *p<0.05 versus sham WT mice; #p<0.05 versus BDL WT mice. 
 
 
We next wanted to specifically evaluate changes in H1HR and H2HR expression 
in small and large cholangiocytes in our models. First, we found a minimal increase in 
H1HR expression in small cholangiocytes, with no change in large cholangiocytes 
following BDL (Figure 16A). Interestingly, there was an upregulation in H1HR expression 
in peripheral, non-biliary cells (Figure 16A). However, we saw a strong and significant 
increase in H2HR predominantly in large cholangiocytes in BDL WT mice when compared 
to sham WT mice (Figure 16B). The expression of both H1HR and H2HR in these various 
cell types was significantly reduced in BDL KitW-sh mice when compared to BDL WT mice 
(Figure 16A and B). Since we primarily found an upregulation in H2HR in large 
cholangiocytes, we evaluated the downstream effectors, cAMP and pERK in these cells. 
We saw a similar trend wherein large cholangiocyte cAMP/pERK expression was 


































































reduced in large cholangiocytes in BDL KitW-sh mice when compared to BDL WT mice 




Figure 16, Assessment of cAMP/pERK Expression Following BDL.   Evaluation of H1HR, H2HR and 
cAMP/pERK expression in WT and Kit
W-sh
 mice subjected to sham or BDL surgery. (A) H1HR expression 
is increased in small ducts and peripheral, non-biliary cells in BDL WT mice when compared to sham WT 
mice; however, H1HR expression is decreased in BDL Kit
W-sh
 mice when compared to BDL WT mice. (B) 
H2HR expression is strongly and predominantly increased in large ducts in BDL WT mice when compared 
to sham WT mice, but this is reduced in BDL Kit
W-sh
 mice. (C) Large duct expression of cAMP is upregulated 
in BDL WT mice when compared to sham WT mice, but decreased in large ducts of BDL Kit
W-sh
 mice. (D) 
Similarly, pERK expression in large ducts is increased in BDL WT mice when compared to sham WT mice; 
however, this is significantly decreased in BDL Kit
W-sh




MC Injection Increases HR Signaling in KitW-sh Mice 
We next evaluated whether the injection of MCs is able to restore H1/H2 HR and 
cAMP/pERK expression in MC-deficient mice. As expected, the injection of MCs 














































sh mice (Figure 17A). Interestingly, MC injection increases hepatic H2HR expression in 
KitW-sh mice (Figure 17B). As well, KitW-sh mice have increased cAMP and pERK 





Figure 17, Determination of H1HR, H2HR, and cAMP/pERK Expression Following MC Injection.   
Evaluation of H1HR, H2HR and cAMP/pERK expression in Kit
W-sh
 mice injected with MCs. (A) H1HR 
expression is slightly increased in small ducts and peripheral, non-biliary cells following MC injection into 
Kit
W-sh
 mice when compared to control injected counterparts. (B) H2HR expression is increased Kit
W-sh
 mice 
injected with MCs. (C) Injection of MCs increases large duct expression of cAMP in Kit
W-sh
 mice. (D) 
Similarly, MC injection increases pERK expression in large ducts in Kit
W-sh
 mice. Images are 80× 
magnification.    
 
 
Loss of MCs Reduces Peribiliary Gland Presence, and Expression of vWF 
and VEGF 
Following BDL in WT mice, there is an increase in the presence of peribiliary 
glands (marked by black arrows) found in close proximity to large bile ducts (indicated by 
the yellow arrow) when compared to sham WT mice (Figure 18A). However, in both sham 
and BDL KitW-sh mice, there is no visible evidence of peribiliary glands (Figure 18A) 
compared to BDL WT mice. Further, VEGF-C expression is significantly reduced in 
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demonstrates an increase in BDL WT mice compared to sham WT mice, and in BDL KitW-
sh mice there is a marked decrease in the expression of vWF compared to BDL WT 
(Figure 18C). Similarly, vWF gene expression is increased in BDL WT mice compared to 
WT mice, and in BDL KitW-sh mice there is a marked decrease in the expression of vWF 
compared to BDL WT mice (Figure 18D). These data indicate that MCs not only influence 
the biliary epithelium, but also the peribiliary glands and the vascular bed during BDL-
induced liver damage. 
 
 
Figure 18, Presence of Peribiliary Glands and Endothelial Cells Following BDL.   Evaluation of 
peribiliary glands and vascular cell presence in WT and Kit
W-sh
 mice subjected to sham or BDL surgery. (A) 
H&E staining reveals the presence of peribiliary glands in BDL WT mice (black arrows) in close proximity 
to large bile ducts (yellow arrow), whereas sham WT mice, and sham and BDL Kit
W-sh
 mice have no visible 
peribiliary glands. (B) VEGF-C expression is increased in total liver from BDL WT mice compared to sham 
WT mice, which is decreased in BDL Kit
W-sh
 mice. (C) vWF expression (green) is upregulated in BDL WT 
compared to sham WT mice, whereas vWF is reduced in sham and BDL Kit
W-sh
 mice. (D) vWF gene 
expression is increased in total liver from BDL WT mice compared to sham WT mice and is reduced in 
BDL Kit
W-sh
 mice compared to BDL WT mice. Data are expressed as mean ± SEM of 6 experiments for 
qPCR. *p<0.05 versus sham WT mice; #p<0.05 versus BDL WT mice. Images are 10× magnification for 
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MC Injection Increases vWF and VEGF Expression in KitW-sh Mice 
There was no significant change in peribiliary gland presence in KitW-sh mice 
injected with MCs versus control mice (not shown). The injection of MCs into KitW-sh mice 
was able to significantly increase vWF expression and VEGF-C gene expression when 





Figure 19, Evaluation of Endothelial Cell Presence and VEGF-C Levels Following MC Injection.   
Determination of vascular cell presence in Kit
W-sh
 mice injected with MCs or vehicle. (A) vWF expression 
(green) is upregulated in Kit
W-sh
 mice injected with MCs when compared to vehicle-injected mice. (B) VEGF-
C gene expression is increased in total liver from Kit
W-sh
 mice injected with MCs when compared to vehicle-
injected mice. *p<0.05 versus Kit
W-sh
 mice. Images are 20× magnification. 
 
 
H2HR Vivo Morpholino Treatment Ameliorates Hepatic Damage, 
Inflammation and Necrosis in Mdr2-/- Mice 
Since we found that (i) MCs primarily regulate large (but not small) biliary 
proliferation, (ii) large cholangiocytes express H2HR, and (iii) H2HR is predominantly 
increased in models of cholestasis, we wanted to further evaluate the role of H2HR 
signaling on large duct damage and subsequent liver injury in the Mdr2-/- mouse model of 
PSC. By H&E staining and serum chemistry, we found that blocking expression of the 






























H2HR by Vivo Morpholino treatment downregulated hepatic damage and serum levels of 
g-GT, a marker of cholangiocyte damage in Mdr2-/- mice, when compared to mismatch 
morpholino controls (Figure 20A and B). Similar to our BDL model, Mdr2-/- mice treated 
with mismatch morpholino had a significant increase in peribiliary gland presence (black 
arrows) surrounding a large duct (yellow arrow). Peribiliary glands were reduced in Mdr2-
/- mice treated with H2HR Vivo Morpholino (Figure 20A). Further, inflammation and 
necrosis were reduced in Mdr2-/- mice treated with H2HR Vivo Morpholinos compared to 




Figure 20, Assessment of Liver Injury and Peribiliary Gland Presence Following H2HR Vivo 
Morpholino Treatment.   Assessment of liver injury in Mdr2
-/-
 mice treated with H2HR Vivo Morpholino. 
(A) H&E staining shows increased portal inflammation, peribiliary fibrosis, large duct damage (yellow arrow) 
and the presence of peribiliary glands (black arrows) in Mdr2
-/-
 mice treated with mismatch morpholinos 
versus WT mice. H2HR Vivo Morpholino treatment reduced these findings in Mdr2
-/-
 mice. (B) Serum levels 
of "-GT (marker of biliary damage) are increased in Mdr2-/- mice treated with mismatch morpholino versus 
WT mice, but this is decreased in Mdr2
-/-
 mice treated with H2HR Vivo Morpholinos. Data are expressed 
as mean ± SEM of 4 experiments for EIA. *p<0.05 versus WT; #p<0.05 versus Mdr2
-/-
 mice + mismatch. 
Images are 20× magnification. 
 

























MCs and the Histamine/H2HR Signaling Pathway Are Decreased in Mdr2-/- 
Mice Treated with H2HR Vivo Morpholinos 
MC infiltration was upregulated in Mdr2-/- mice treated with mismatch morpholinos 
(similar to previous studies (15, 37, 100)), as demonstrated by immunohistochemical 
assessment of mMCP-1 and qPCR for chymase and c-Kit in total liver, when compared 
to WT mice (Figure 21A-C). However, H2HR Vivo Morpholino treatment decreased MC 
number and expression of chymase and c-Kit in Mdr2-/- mice when compared to the 
mismatch--treated group (Figure 21A-C). 
Similarly, when Mdr2-/- mice were treated with mismatch morpholinos, serum 
histamine secretion significantly increased compared to WT mice; however, treatment 
with H2HR Vivo Morpholinos decreased histamine secretion in Mdr2-/- mice compared to 
mismatched morpholino treatment (Figure 22A). Additionally, H2HR and cAMP 
expression were increased in large cholangiocytes in Mdr2-/- livers following mismatch 
morpholino treatment when compared to WT mice, but these parameters were reduced 







Figure 21, Visualization of Hepatic MCs and MC Marker Expression Following H2HR Vivo 
Morpholino Treatment.   Determination of MC presence in Mdr2
-/-
 mice treated with H2HR vivo 
morpholinos. (A) By staining for mMCP-1 (MC marker) there was increased MC presence in Mdr2
-/-
 mice 
treated with mismatch morpholinos as compared to WT mice; however, MC number was reduced in in 
Mdr2
-/-
 mice treated with H2HR vivo morpholinos. (B) There was increased gene expression of chymase 
(MC marker) in total liver in mismatch-treated Mdr2
-/-
 mice compared to WT mice, but this was reduced 
following H2HR vivo morpholino treatment. (C) Similarly, gene expression of c-Kit (MC) in total liver was 
increased in Mdr2
-/-
 mismatch-treated mice compared to WT mice, but decreased following H2HR vivo 
morpholino treatment. Data are expressed as mean ± SEM of 4 experiments for qPCR. *p<0.05 versus 
WT; #p<0.05 versus Mdr2
-/-
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Figure 22, Determination of H2HR and cAMP Expression, and Histamine Secretion Following H2HR 
Vivo Morpholino Treatment.   Assessment of H2HR/cAMP expression and histamine secretion in Mdr2
-/-
 
mice treated with H2HR Vivo Morpholinos or mismatch. (A) By staining in liver sections, we noted an 
increase in large duct H2HR expression in Mdr2
-/-
 mice treated with mismatch as compared to WT mice; 
however, this was reduced in Mdr2
-/-
 mice treated with H2HR Vivo Morpholinos. (B) There was increased 
histamine secretion in mismatch-treated Mdr2
-/-
 mice compared to WT, but this was reduced following 
H2HR Vivo Morpholino treatment. (C) Large duct expression of cAMP (downstream of H2HR) was 
increased in Mdr2-/- mismatch mice, but decreased in Mdr2-/- mice treated with H2HR Vivo Morpholinos. 
Data are expressed as mean ± SEM of 4 experiments for EIA. *p<0.05 versus WT; #p<0.05 versus Mdr2
-/-
 




H2HR Vivo Morpholino Treatment Reduces Large IBDM in Mdr2-/- Mice 
We next evaluated large IBDM and large cholangiocyte proliferation by 
immunohistochemical assessment of CK-19 and Ki-67 expression. We found that 
blocking H2HR using Vivo Morpholino treatment decreased large IBDM and large biliary 
proliferation, respectively, in Mdr2-/- mice compared to Mdr2-/- mice treated with mismatch 
morpholino (Figure 23A and B) This compliments our earlier studies demonstrating that 
large cholangiocytes primarily express H2HR, and that this receptor may preferentially 
mediate large cholangiocyte proliferation during cholestasis (7, 15). 







































Figure 23, Evaluation of Large IBDM and Large Cholangiocyte Proliferation Following H2HR Vivo 
Morpholino Treatment.   Evaluation of large duct mass and proliferation in Mdr2
-/-
 mice treated with H2HR 
Vivo Morpholinos or mismatch. (A) Immunohistochemistry for CK-19 demonstrated that large duct mass 
was increased in Mdr2
-/-
 mice treated with mismatch as compared to WT mice; however, large duct mass 
was significantly reduced in Mdr2
-/-
 mice treated with H2HR Vivo Morpholino. (B) Similarly, we found a 
significant increase in large cholangiocyte proliferation, as determined by staining for Ki67, in mismatch-
treated Mdr2
-/-
 mice compared to WT mice; however, large cholangiocyte proliferation was reduced 
following H2HR Vivo Morpholino treatment in Mdr2
-/-
 mice compared to mismatch treatment. Data are 
expressed as mean ± SEM of 10 experiments. *p<0.05 versus WT; #p<0.05 versus Mdr2
-/-
 mice + 




Inflammation, HSC Activation and Liver Fibrosis Are Decreased in Mdr2-/- 
Mice Treated with H2HR Vivo Morpholinos 
 The presence of Kupffer cells (marked by F4/80 expression) was increased in 
Mdr2-/- mice treated with mismatched morpholinos when compared to WT mice, but this 
was reduced in Mdr2-/- mice treated with H2HR Vivo Morpholinos (Figure 24A). Further, 
the gene expression of CCL2 and CCL5 increased in total liver of Mdr2-/- mice treated 
with mismatched morpholino when compared to WT mice, but was subsequently reduced 























CK-19 WT Mdr2-/- + mismatch Mdr2-/- + Vivo Morpholino








































Figure 24, Visualization of Kupffer Cell Number, and CCL2 and CCL5 Expression Following H2HR 
Vivo Morpholino Treatment.   Assessment of Kupffer cell number and liver inflammation in Mdr2
-/-
 mice 
treated with H2HR Vivo Morpholinos or mismatch. (A) Staining for F4/80 (marker of Kupffer cells) showed 
that Kupffer cell number was increased in Mdr2
-/-
 mice treated with mismatch as compared to WT mice, but 
was decreased following H2HR Vivo Morpholino treatment in Mdr2
-/-
 mice. (B) As determined by qPCR in 
total liver, gene expression of CCL2 and CCL5 were significantly increased in Mdr2
-/-
 mismatch-treated 
mice compared to WT mice; however, CCL2 and CCL5 gene expression decreased following H2HR Vivo 
Morpholino treatment in Mdr2
-/-
 mice compared to mismatch treatment. Data are expressed as mean ± SEM 
of 4 experiments for qPCR. *p<0.05 versus WT; #p<0.05 versus Mdr2
-/-
 mice + mismatch. Images are 20× 




Sirius Red staining and hydroxyproline content both demonstrated an increase in 
collagen deposition in Mdr2-/- mice treated with mismatched Vivo Morpholinos that was 
significantly reduced in Mdr2-/- mice treated with H2HR Vivo Morpholinos (Figure 25A and 
B). Similarly, HSC activation decreased in Mdr2-/- mice treated with H2HR Vivo 
Morpholinos compared to mismatch treatment, as shown by immunofluorescence for 
SYP-9 (Figure 26A).  
F4/80




























































A hallmark feature of increased hepatic fibrosis is elevated TGF-b1 expression and 
secretion. Serum levels of TGF-b1 increased in Mdr2-/- mice treated with mismatched 
Vivo Morpholinos, which was significantly reduced in Mdr2-/- mice treated with H2HR Vivo 
Morpholinos (Figure 26B). In addition, by qPCR in isolated large cholangiocytes and 
immunofluorescence in liver sections, we found that TGF-b1 expression decreases in 
Mdr2-/- mice treated with the H2HR Vivo Morpholinos compared to Mdr2-/- mice treated 





Figure 25, Determination of Liver Fibrosis Following H2HR Vivo Morpholino Treatment.   
Determination of liver fibrosis in Mdr2
-/-
 mice treated with H2HR Vivo Morpholino or mismatch. (A) Sirius 
Red staining and semi-quantification demonstrated a significant increase in collagen deposition in Mdr2
-/-
 
mice treated with mismatch as compared to WT mice, but this was decreased following H2HR Vivo 
Morpholino treatment in Mdr2
-/-
 mice as compared to mismatch treatment. (B) In total liver, there was an 
increase in hydroxyproline content in Mdr2
-/-
 mismatch-treated mice compared to WT mice; however, 
hydroxyproline content was significantly decreased following H2HR Vivo Morpholino treatment in Mdr2
-/-
 
mice compared to mismatch treatment. Data are expressed as mean ± SEM of 10 experiments for Sirius 
Red and 4 experiments for hydroxyproline. *p<0.05 versus WT; #p<0.05 versus Mdr2
-/-
 mice + mismatch. 




















































Figure 26, Evaluation of HSC Activation and TGF-b1 Secretion Following H2HR Vivo Morpholino 
Treatment.   Evaluation of HSC activation and TGF-#1 levels in Mdr2-/- mice treated with H2HR Vivo 
Morpholinos or mismatch. (A) Immunofluorescence for SYP-9 (green) showed increased HSC activation in 
Mdr2
-/-
 mismatch mice as compared to WT mice, but this was decreased following H2HR Vivo Morpholino 
treatment. (B) Serum TGF-#1 serum levels were increased in Mdr2-/- mismatch-treated mice compared to 
WT mice, but significantly decreased in Mdr2
-/-
 mice treated with H2HR Vivo Morpholinos. (C) Gene 
expression of TGF-#1 was increased in large cholangiocytes in Mdr2-/- mismatch-treated mice compared 
to WT mice. H2HR Vivo Morpholino treatment reduced large cholangiocyte TGF-#1 gene expression 
compared to mismatch treatment. (D) Hepatic expression of TGF-#1 was increased in Mdr2-/- mismatch-
treated mice compared to WT mice, but reduced following H2HR Vivo Morpholino treatment. Data are 
expressed as mean ± SEM of 4 experiments for EIA and 4 experiments for qPCR. *p<0.05 versus WT; 
#p<0.05 versus Mdr2
-/-




Inhibition of H2HR by Vivo Morpholino Treatment Decreases Angiogenesis 
and Large Cholangiocyte VEGF Expression/Secretion in Mdr2-/- Mice 
 In Mdr2-/- mice treated with H2HR Vivo Morpholinos we found a decrease in vWF 
expression shown by immunofluorescence and qPCR in total liver compared to Mdr2-/- 
mice treated with mismatch Vivo Morpholinos (Figure 27A and B). VEGF-A/C gene 
A B
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expression increased in large cholangiocytes isolated from Mdr2-/- mismatch-treated mice 
was significantly reduced in large cholangiocytes isolated from Mdr2-/- mice treated with 
H2HR Vivo Morpholinos (Figure 27C and D). Finally, VEGF-A secretion was evaluated in 
large cholangiocyte supernatant and, in Mdr2-/- mismatch-treated mice, there was an 
increase in VEGF-A levels that was decreased in large cholangiocyte supernatant from 
Mdr2-/- mice treated with H2HR Vivo Morpholinos (Figure 27E). These data support our 
previous work demonstrating that histamine and HRs regulate angiogenesis and VEGF 




Figure 27, Assessment of Hepatic vWF Expression, Large Cholangiocyte VEGF-A/C Expression and 
Large Cholangiocyte VEGF-A Secretion Following H2HR Vivo Morpholino Treatment.   Measurement 
of angiogenesis and VEGF expression/secretion in Mdr2
-/-
 mice treated with H2HR Vivo Morpholino or 
mismatch. (A) Immunofluorescence for vWF (green) demonstrated enhanced vWF expression in Mdr2
-/-
 
mismatch-treated mice as compared to WT mice; however, vWF expression was reduced in H2HR Vivo 
Morpholino-treated Mdr2
-/-
 mice. (B) Additionally, the gene expression of vWF was increased in total liver 
from Mdr2
-/-
 mismatch-treated mice compared to WT mice, but significantly decreased in Mdr2
-/-
 H2HR Vivo 
Morpholino-treated mice. (C) Gene expression of VEGF-A and (D) VEGF-C was increased in large 
cholangiocytes in Mdr2
-/-
 mismatch-treated mice compared to WT mice. H2HR Vivo Morpholino treatment 
reduced large cholangiocyte gene expression of VEGF-A and VEGF-C compared to mismatch treatment. 
(E) Similarly, large cholangiocyte secretion of VEGF-A increased in Mdr2
-/-
 mismatch-treated mice 
compared to WT, but reduced following H2HR Vivo Morpholino treatment. Data are expressed as mean ± 
SEM of 4 experiments for qPCR and 4 experiments for EIA. *p<0.05 versus WT; #p<0.05 versus Mdr2
-/-
 



















































































































In Vitro, MCs Migrate Towards Damaged Large, But Not Small, 
Cholangiocytes 
To evaluate the capacity of MCs to migrate towards injured small and large 
cholangiocytes, we treated small and large cholangiocytes with LPS in vitro prior to 
placing the damaged cholangiocytes in the lower well of Boyden chambers and loading 
the top well with MCs. Following 24 hrs of incubation, we found that MCs migrate towards 
both unstimulated small and large cholangiocytes when compared to control wells 
containing no cells in the lower well (Figure 28). Interestingly, small cholangiocytes 
treated with LPS show no change in MC migration when compared to undamaged 
controls; however, large cholangiocytes treated with LPS significantly increased MC 
migration when compared to controls (Figure 28). These data confirm our in vivo findings 







Figure 28, In Vitro Determination of MC Migration Towards Small or Large Cholangiocytes Treated 
with LPS.   Assessment of MC migration to small and large cholangiocytes treated with LPS (to induce 
damage). To evaluate MC migration, we loaded the top well of Boyden chambers with MCs and the bottom 
chamber with no cells (control), untreated small or large cholangiocytes, or small or large cholangiocytes 
treated with LPS (100 ng/ml) for 24 hrs. As shown by Toluidine blue staining, MC migration towards 
untreated small and large cholangiocytes increased compared to control wells containing no cells. However, 
MC migration increased towards damaged large, but not small, cholangiocytes when compared to untreated 
counterparts. n=10 pictures evaluated for Toluidine blue staining. *p<0.05 vs control; #p<0.05 vs Large; 




In Vitro, MCs Promote Large Cholangiocyte Damage and H2HR/cAMP 
Signaling 
Since we have verified that MCs primarily interact with large but not small 
cholangiocytes, we utilized cultured large cholangiocytes for the remainder of our studies. 
We next evaluated phenotypic changes in large cholangiocytes that were treated with 
supernatants from either cultured MCs or MCs pre-treated with the HDC inhibitor, a-Me 
(to block histamine synthesis in MCs). We noted that large cholangiocytes exposed to 
supernatants from untreated MCs demonstrated increased proliferation as shown by 
PCNA immunofluorescence (Figure 29A). Of note, we found that large cholangiocytes 
treated with supernatants from untreated MCs had an increase in cellular senescence as 
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demonstrated by p18 expression (Figure 29B). However, both proliferation and 
senescence were decreased in large cholangiocytes that were treated with supernatants 
from MC pre-treated with a-Me (Figure 29A and B). We next evaluated HR expression in 
large cholangiocytes and found that H1HR expression did not significantly change in large 
cholangiocytes treated with supernatants from control MCs or aMe-treated MCs (Figure 
29C). As expected, H2HR expression was significantly upregulated in large 
cholangiocytes treated with MC supernatants, but this change was not seen in large 
cholangiocytes treated with supernatants from aMe-treated MCs (Figure 29D). These 
changes mimic our in vivo findings where we see a strong increase in H2HR expression, 
over H1HR, in large cholangiocytes during cholestasis. 
We next examined the downstream effectors of H2HR signaling to determine if 
MC-derived histamine mediates these changes. We found that both cAMP and pERK 
expression were increased in large cholangiocytes treated with MC supernatants; 
however, these findings were significantly reduced in large cholangiocytes treated with 
supernatants from MCs pre-treated with a-Me (Figure 29E and F). Similarly, large 
cholangiocytes treated with MC supernatants had increased cellular cAMP levels, which 
were significantly reduced in large cholangiocytes stimulated with supernatants from MCs 
pre-treated with a-Me (Figure 30). Our data indicate that MC-derived histamine promotes 





Figure 29, Visualization of Large Cholangiocyte Expression of PCNA, p18, H1HR, H2HR and pERK 
Following Stimulation with MC Supernatants.   Visualization of large cholangiocyte phenotype following 
treatment with supernatants from MCs and MCs pre-treated with !Me. (A) Large cholangiocytes treated 
with MC supernatants displayed increased proliferation, as shown by PCNA staining, but this was 
decreased in large cholangiocytes treated with supernatants from MCs pre-treated with !Me. (B) 
Interestingly, MC supernatants promoted large cholangiocyte senescence (p18 expression), but this was 
reduced in large cholangiocytes treated with supernatants from MCs pre-treated with !Me. (C) There was 
no significant change in H1HR expression following stimulation with MC supernatants or supernatants from 
MCs pre-treated with !Me. (D) Stimulation with MC supernatants upregulated large cholangiocyte H2HR 
expression, but this was not seen with supernatants from MCs pre-treated with !Me. (E) Large 
cholangiocyte pERK (downstream of H2HR/cAMP) expression was enhanced following stimulation with MC 
supernatants, which was not noted in large cholangiocytes treated with supernatants from MCs pre-treated 
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Figure 30, In Vitro Measurement of cAMP Levels in Large Cholangiocytes Following Stimulation 
with MC Supernatants.   Measurement of cellular cAMP levels in large cholangiocytes following treatment 
with supernatants from untreated MCs and MCs treated with !Me. Cellular levels of cAMP, downstream of 
H2HR activation, were increased in large cholangiocytes treated with untreated-MC supernatants; however, 
cAMP levels were decreased when large cholangiocytes were treated with !Me-treated MC supernatants. 





















The main focus of our lab has been to identify the role of MCs and their derived 
factors on the promotion of damage during various models of liver injury. Our previously 
published findings have extensively demonstrated that MCs migrate towards bile ducts 
during models of cholestasis, e.g., PSC and CCA, and inhibition of MC activation in these 
settings is protective (15, 37, 94, 100). However, the damage seen in these different 
situations is variable and dependent on the heterogeneity of the biliary tree. Considering 
the significant differences in small and large cholangiocytes, and their responses to injury, 
evaluating MC impact on these different subsets of cells is intuitive. PSC is associated 
with large duct damage and patients with PSC are also at a higher risk for developing 
large ductal CCA, therefore the investigation of mechanisms regulating large duct 
damage is clinically warranted. 
During cholestatic injury, cholangiocytes hyper-proliferate in order to repair the 
injured biliary tree. Following BDL, MCs begin to infiltrate the liver beginning at day 2 with 
hepatic MC number peaking at day 7, and sustained through day 14 (101). Interestingly, 
MC infiltration does not occur until cholangiocytes have begun to proliferate, suggesting 
that MC infiltration occurs in response to cholangiocyte damage and supports increased 
cholangiocyte proliferation following injury. We have also found that MC infiltration is 
increased even as early as 12 weeks of age and can be seen as late as 52 weeks of age 
                                               
*Part of this chapter is reprinted with permission from “Bile Duct Ligation-Induced Biliary Hyperplasia, Hepatic Injury, and Fibrosis 
Are Reduced in Mast Cell-Deficient KitW-sh Mice” by Hargrove L, Kennedy L, Demieville J, Jones H, Meng F, DeMorrow S, Karstens 
W, Madeka T, Greene J Jr, Francis H, 2017. Hepatology, 65, 1991-2004, Copyright 2017 by John Wiley and Sons. 
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in the Mdr2-/- mouse; however, a time-course study is needed to determine when MCs 
infiltrate Mdr2-/- livers and how MC infiltration correlates with increased bile duct damage. 
 Our BDL KitW-sh study is the first to determine the impact of MC deficiency on biliary 
proliferation following BDL, although it has been shown that MCs promote muscle cell 
hyperplasia and hypertrophy during eosinophilic esophagitis (127). Furthermore, 
proliferating cholangiocytes need a consistent supply of growth factors to support their 
sustained growth. Activated MCs secrete numerous growth factors and pre-formed 
mediators, such as histamine, VEGF and TGF-b1, that aid in the hyperproliferation of 
cholangiocytes during cholestasis (15, 36, 79, 80, 100). However, TGF-b1 induces 
cholangiocyte senescence (12), and we have shown that loss of MCs reduces biliary 
senescence in a model of NAFLD (9). While MCs promote proliferation, they may 
inadvertently increase biliary senescence as well. Indeed, one study found that 
stabilization of MCs attenuated senescence of epididymal white adipose tissue in mice 
fed a high fat diet (128), and this supports our in vivo MC injection studies as well as our 
in vitro analysis.  
The interesting take on these findings involves the heterogeneity among 
cholangiocytes and how they are impacted by MCs and MC-derived mediators. It has 
been hypothesized that large cholangiocytes are more susceptible to damage, whereas 
small cholangiocytes are more resistant (4). Following damage, such as in BDL or in 
Mdr2-/- mice, there is an initial upregulation of biliary proliferation but after sustained 
periods senescent large cholangiocytes become apparent (12). This concept is supported 
by work presented here; however, we add MCs to the equation by noting that lack of MCs 
blocks the development of senescence in large cholangiocytes. Further, in vitro analysis 
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determined that blocking MC-derived histamine synthesis and/or release blocks the 
development of large cholangiocyte senescence. However, it is unclear if histamine 
signaling directly mediates large cholangiocyte senescence or if it is an indirect effect. 
 We have repeatedly demonstrated that histamine is a growth promoting factor for 
cholangiocytes (7, 9, 109), and others have found histamine to be pro-inflammatory (114, 
129); therefore, it is possible that large cholangiocytes, which are continually exposed to 
MC-derived histamine, become highly inflammatory and secrete various cytokines that 
induce senescence in other neighboring large cholangiocytes. This concept is supported 
by work wherein large cholangiocyte-derived extracellular vesicles induce inflammatory 
responses in other large cholangiocytes in vitro (10). While cholangiocytes can be 
categorized into small and large populations, these sub-populations can be even further 
divided based on cell phenotype. This complex signaling mechanism requires further 
investigation to fully understand how a sub-population of cholangiocytes can have an 
even further degree of heterogeneity. 
MCs do not infiltrate the liver until bile duct number begins to increase; therefore, 
proliferating cholangiocytes, that have entered a neuroendocrine phenotype, potentially 
release factors that promote the migration of MCs to peribiliary areas. It has been 
demonstrated that there is increased cholangiocyte expression of SCF during human 
PSC (102), and we have found that SCF secreted from CCA cells induces MC migration 
through binding with c-Kit (94). During cholestasis, cholangiocytes have increased 
expression of sphingosine-1-phosphate and TGF-b1 that are known to be strong 
chemoattractants for MCs (85, 130, 131). Additionally, we found that damaged large 
cholangiocytes (induced by LPS stimulation in vitro) increased MC migration that was not 
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induced by damaged small cholangiocytes. Differences in secreted factors between 
damaged small and large cholangiocytes may account for the variation in MC migration. 
For example, sphingosine-1-phosphate is predominantly found on large instead of small 
cholangiocytes during bile acid-mediated cholestatic injury (130). Indeed, bioinformatic 
analysis has shown that large cholangiocytes display increased immune/inflammatory 
responses (132), and these transcriptional differences may impact MC migration toward 
small versus large ducts. 
Kupffer cells mediate inflammatory changes in the liver during injury (23, 126). Our 
data indicate that increased MC presence increases Kupffer cell number; however, little 
work has been done to evaluate the potential signaling mechanisms between these two 
cell types. It has been shown that MC and Kupffer cell number simultaneously increase 
during hepatocellular carcinoma (HCC) progression (81), but interaction between the two 
cell types was not determined. It has been shown that MC-derived IL-1b promotes skin 
inflammation during cryopyrin-associated periodic syndromes (133). As well, cultured 
human MCs secrete IL-6 (134), and isolated human intestinal MCs express TNF-a (80). 
IL-1b, IL-6 and TNF-a promote Kupffer cell pro-inflammatory activities; therefore, MCs 
may play a direct role in Kupffer cell activation during cholestasis. In support of this, we 
have found in vitro that cultured MC supernatants promote Kupffer cell activation and 
inflammation (Kennedy and Francis, unpublished observations 2018). While MCs may 
mediate Kupffer cells directly there may be an unstudied role for MC mediation of large 
cholangiocytes that in turn affects Kupffer cell activation. However, it is not known if large 
cholangiocytes, small cholangiocytes or both mediate Kupffer cell activation and the 
recruitment of blood-derived monocytes. Considering that large cholangiocytes have a 
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higher capacity for immune and inflammatory responses based on transcriptomic 
analysis, this subset of cholangiocytes may have a more prominent role in the pro-
inflammatory activation of Kupffer cells and the infiltration of macrophages (132). 
However, it has been shown that human PSC cholangiocytes have increased NFkB 
signaling that promotes the expression of cytokines and chemokines (135), and these 
factors may mediate Kupffer cell activation and the inflammatory response. Additionally, 
whether MCs promote Kupffer cell activation remains unknown. It is apparent that more 
research is needed to understand (i) how MCs may promote Kupffer cell activation and 
(ii) how MC interaction with cholangiocytes may mediate inflammatory properties in 
Kupffer cells.  
The role of MCs during fibrogenesis remains controversial. Studies have 
demonstrated that (i) MCs promote tissue fibrosis; (ii) loss of MCs induces fibrosis leading 
to a worsening condition and (iii) MCs play no real role in tissue fibrosis. A study 
using MC-deficient rats found vigorous interstitial fibrosis in the kidney compared to 
control animals suggesting that, in this model, MCs are beneficial to the fibrotic process 
(136). In support of our study, it has been demonstrated that MCs promote and drive 
cardiac fibrosis, and MC-deficient mice are protected from this event (137). In contrast to 
our work, another study found that MCs have no consequence on the development of 
liver fibrosis in rats and mice subjected to BDL (138); whereas, our present studies 
indicate that MC introduction induces robust hepatic fibrosis, and there is decreased 
fibrotic progression in BDL KitW-sh compared to the BDL WT. However, their study 
involved 21-day BDL; therefore, the reaction of the biliary tree and infiltration of MCs 
during early events of fibrosis were not evaluated (138). In contrast, our study evaluated 
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BDL-induced damage no later than 7 days when the biliary tree has been shown to be 
fully reactive to damage and MC infiltration peaks (101). Another obvious difference is the 
rodent model of MC deficiency used. The other authors chose Ws/Ws rats and male 
WBB6F1-+/+ and W/Wv mice, whereas we employed KitW-sh mice that have a different 
phenotype from these models.  
It has not been determined whether large or small cholangiocytes mediate HSC 
activation and subsequent liver fibrosis. In Mdr2-/- mice (that present with increased large 
duct damage) there is increased biliary senescence driven by B-cell lymphoma-extra 
large (Bcl-xL) expression (108). Inhibition of Bcl-xL significantly decreased cholangiocyte 
senescence, thus reducing fibroblast activation and liver fibrosis (108). Understanding the 
differential roles of heterogenous cholangiocytes on the fibrogenic process will be a 
necessary step in understanding how to treat and monitor different cholangiopathies. 
One prominent driver of collagen production in HSCs and a contributor to fibrosis 
is TGF-β1, which is found within MCs and can be released upon activation. TGF-β1 
perpetuates HSC transformation into myofibroblasts, thus inducing fibrosis during 
disease. We found that ablation of MCs significantly reduces BDL-induced TGF-β1 
expression and secretion. In addition, TGF-β1 levels were increased in KitW-sh mice 
injected with cultured MCs, supporting the concept that MCs are an important source of 
TGF-β1 during fibrosis progression. Supporting this is the observation that histamine or 
angiotensin released from MCs induces secretion of TGF-β1 from fibroblasts that, in turn, 
increases collagen synthesis and pulmonary fibrosis induction. When MCs were absent, 
these events were inhibited (139). Furthermore, implanted MCs (from WT mice) into MC-
deficient mice increases angiogenesis and cardiac function via augmented fibroblast 
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activity and transformation that was TGF-β1-dependent (140), again pinpointing MC-
regulated TGF-β1 as a key player in fibrosis. The full contribution of MCs to liver fibrosis 
is not completely defined; however, we present strong data herein showing that MCs play 
a critical and detrimental role in hepatic fibrosis through TGF-β1.  
MCs release numerous factors, but a prominent component of MCs is histamine, 
which has been recognized now to be more than just a mediator of allergic events (79). 
We have demonstrated in numerous studies that histamine is a trophic, growth-promoting 
factor that induces biliary hyperplasia, hepatic fibrosis and CCA progression (7, 94, 100, 
109, 110). Cholangiocytes secrete minimal amounts of histamine and are able, through 
autocrine signaling, to regulate CCA growth (141); however, MCs are the major producers 
of histamine in the body. Stabilization of MCs using cromolyn sodium decreases biliary 
hyperplasia, fibrosis and CCA growth, pinpointing MC-derived mediators as a culprit in 
various cholangiopathies (15, 37, 94, 100). In our current study, we measured histamine 
secretion and H1/H2 HR expression. As expected, all of these factors were upregulated 
in BDL WT and Mdr2-/- mice, but reduced in BDL KitW-sh mice and Mdr2-/- mice treated 
with H2HR Vivo Morpholinos. These findings further suggest that histamine itself, and 
histamine receptor signaling, are drivers of biliary hyperplasia and hepatic fibrosis. 
Histamine signaling through H2HR on large cholangiocytes may drive biliary and liver 
damage during BDL and in the Mdr2-/- mouse model of PSC. In support of this, our lab 
has previously shown that normal rats treated with an H2HR agonist have increased large 
cholangiocyte proliferation mediated by cAMP-dependent signaling mechanisms (7). 
Furthermore, while our mice are MC-deficient, they still receive histidine in their standard 
chow, and since cholangiocytes secrete small amounts of histamine this may account for 
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the minimal amount of histamine found in the serum and is consistent with other studies 
using MC-deficient models or HDC-deficient mice (109).  
Besides being a growth-promoting factor, histamine regulates other factors 
including VEGF during BDL-induced injury and in Mdr2-/- mice (100, 109, 110). The 
peribiliary plexus is a dynamic vascular structure that supports the nutritional needs of the 
biliary tree and provides the largest source of VEGF in the liver, although cholangiocytes 
secrete VEGF and express VEGF-R2 and VEGF-R3. MCs also express VEGF receptors 
and produce VEGF when activated (52, 142). In melanoma, activation of MCs by IgE 
induces VEGF release that promotes tumor growth (52). In our study we found that 
BDL KitW-sh mice and Mdr2-/- mice treated with H2HR Vivo Morpholino have lower levels 
of VEGF-C and further, the vascular bed is altered in these mice as shown by decreased 
expression of vWF. KitW-sh mice injected with MCs had increased VEGF-C expression as 
well as an increase in endothelial cell presence as shown by an increase in total vWF 
expression. Ghosh et al. found no difference in angiogenic signaling in the MC-deficient 
WBB6F1-W/W(V) mice compared to controls following implantation of cotton threading to 
induce granulation tissue formation; however, HDC knockout mice displayed marked 
alterations in angiogenic signaling (143). Our study demonstrates no significant difference 
in vascular remodeling between sham WT and sham KitW-sh mice implying that the effect 
of MCs is enhanced during pathological conditions. These findings demonstrate that there 
is a significant loss of biliary reaction in MC-deficient mice that alters the vascular bed, as 
demonstrated by reduced vWF expression. Since vWF is expressed by endothelial cells, 
we believe there may be crosstalk between MCs, cholangiocyte and endothelial cells, but 
more work is necessary to understand exactly how the endothelial cells are impacted. It 
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is important to note that the peribiliary vascular plexus is primarily found surrounding the 
large ducts but becomes smaller and more sparse when extended towards the small 
ducts of the intrahepatic biliary network (53). When large ducts show enhanced 
inflammation, such as during hepatolithiasis, PSC and extrahepatic biliary obstruction, 
the vessels increase in number, and during later stages of disease the vessels further 
increase in number and become dilated (53). However, it has been observed in PSC 
patients with little bile duct injury that the duct/vessel ratio is near normal (144). There is 
a delicate balance between large biliary growth and increased vessel number/size that 
seems to mediate disease progression, and this is supported by our work using H2HR 
Vivo Morpholinos. It is apparent that vessel growth is secondary to increased bile duct 
number, but in turn, the bile ducts need the vascular plexus to maintain their growth. 
Changes in the peribiliary vascular plexus during cholestasis may be directly mediated by 
MCs, but may also occur indirectly by MCs promoting large cholangiocyte proliferation, 
which signals to the vascular plexus to increase growth. 
In support of the concept that MCs can influence peribiliary gland development, a 
study examining mammary glands in KitW-sh mice found that the development of glands, 
but not their function, was altered compared to WT counterparts (145). These mice were 
still able to lactate and their mammary glands functioned properly even though the 
mammary glands were significantly altered during development. The changes 
demonstrated in our current study regarding IBDM and biliary proliferation coupled with 
the presence or absence of peribiliary glands suggests that the peribiliary glands are not 
the sole source of proliferating cholangiocytes. This is supported by numerous studies 
demonstrating that other factors including secretin, serotonin and VEGF are secreted 
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from cholangiocytes, which can subsequently influence biliary proliferation in both normal 
and damaged states (8, 51, 107). However, it is important to note that the peribiliary 
glands are preferentially located around the large bile ducts (19). These structures contain 
seromucinous acini and may be a potential stem cell niche for the maintenance of the 
large ducts of the biliary tree, with the small ducts having their own stem cell population 
termed hepatic progenitor cells (17, 19, 146). Considering these glands reside near large 
ducts, and activate in response to substantial damage, it is important to note that inhibition 
of large cholangiocyte H2HR by Vivo Morpholino treatment in Mdr2-/- mice reduced 
peribiliary gland presence, further signifying the close interaction between large ducts and 
peribiliary glands during injury. Patients with PSC have increased peribiliary gland 
hyperplasia that is coupled with progressive biliary fibrosis, and expansion of the 
peribiliary glands correlated with enhanced stem cell number in these glands (17). One 
day following BDL there is enhanced expression of stem/progenitor markers in the 
peribiliary glands along with enhanced proliferation of these biliary stem cells (18). The 
current hypothesis is that these proliferating biliary stem cells enter a transit-amplifying 
state and undergo differentiation to become large cholangiocytes, thus restoring the large 
cholangiocyte population (that underwent senescence or apoptosis induced by damage) 
or increasing large cholangiocyte number to support the growing biliary tree (17, 18). 
Since MCs begin to migrate to the liver 2 days following BDL, but peribiliary gland 
presence is noted 1 day following BDL, the increased stem/progenitor cell proliferation 
and differentiation may promote the infiltration of MCs. Furthermore, in KitW-sh mice, we 
see an increase in small duct mass with a decrease in large duct mass compared to WT 
mice, and this finding is more prominent in BDL KitW-sh mice compared to BDL WT mice. 
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MCs may support the needs of the peribiliary glands and loss of MCs reduces their 
proliferative capacity, thereby reducing the ability of large ducts to repair themselves, 
leading to compensatory growth of the small ducts to help alleviate damage. 
Clinically speaking, the depletion of MCs throughout the whole body is not likely to 
be a healthy scenario as they are necessary during wound healing, but mechanisms to 
block MCs and the mediators they release may rescue the liver from biliary damage, 
hepatic fibrosis and vascular bed alteration. Cromolyn sodium is one such drug that 
targets MC activation, and treatment with cromolyn sodium inhibits biliary hyperplasia and 
hepatic fibrosis (37, 100). However, there are other factors to consider, as we have 
described in our study, including TGF-β1 and VEGF. Potential candidates for therapy 
might include drugs to target and inhibit MC migration (SCF inhibitors) in conjunction with 
compounds that block VEGF or TGF-β1 release from MCs. Further, microRNAs are being 
investigated as potential mechanisms to regulate MC activation. For example, miR-223 
targets insulin-like growth factor 1 receptor (IGF-1R) in MCs, promoting degranulation 
and decreasing the PI3K/Akt pathway (147). However, looking downstream of MC 
activation, blocking histamine signaling (released by MCs and interacting with 
cholangiocytes) may be a second avenue for the treatment of cholangiopathies. Our 
previously published work as well as this study identify a significant increase in biliary 
H2HR in BDL mice, Mdr2-/- mice and human PSC (15). We have also found that treatment 
with the an over-the-counter H2HR antagonist, ranitidine, significantly reduced biliary 
hyperplasia, liver fibrosis and CCA progression (15). Others have found that ranitidine 
treatment for gastroesophageal reflux disease in infants decreased symptom score, and 
was deemed safe for treatment (148). Furthermore, ranitidine treatment shows a strong 
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antioxidant and protective effect in mice treated with CCl4 to induce hepatic damage 
(149). Interestingly, this study found that ranitidine had the strongest effect over the other 
H2HR antagonists, cimetidine and famotidine (149). However, these publications did not 
delve into the specific hepatic cell types influenced by H2HR antagonism. Based on our 
findings that (i) HRs are prominently expressed by cholangiocytes versus other liver cells 
types and (ii) that H2HR is only increased in large cholangiocytes during models of 
cholestasis, it is plausible that liver damage is directly mediated by large cholangiocyte 
H2HR signaling. However, H2HR antagonists may also work to decrease MC migration 
and activation to the liver, since MCs express this receptor as well. Further studies are 
necessary to identify the most efficacious H2HR antagonist for the treatment of 
cholestatic diseases, the specific cell types influenced by H2HR antagonist treatment and 
whether targeting specific HRs is necessary for the treatment of different liver diseases 
(i.e. large duct PSC, small duct PSC and PBC). 
In conclusion, we have shown that MCs are prominent regulators of biliary 
hyperplasia, hepatic fibrosis and vascular bed dysfunction demonstrated by the BDL 
model, through direct injection of MCs into deficient mice and treatment of Mdr2-/- mice 
with H2HR vivo-morpholino. Our studies reveal a synergistic interplay between MCs, 
cholangiocytes and HSCs, demonstrating the importance of cellular paracrine signaling 
during disease progression. Since MCs that infiltrate the liver following damage are not 
resident liver cells, inhibition or knockdown of MCs or MC components are likely 
therapeutic approaches for patients suffering from cholangiopathies. Furthermore, MCs 
have a significant impact on large cholangiocyte damage and function during cholestatic 
injury mediated by H2HR/cAMP/pERK signaling, and modulation of this signaling 
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mechanism via H2HR antagonist treatment may be a second therapeutic option for 
patients suffering from large duct damage. Our study warrants the future investigation of 
modulation of MCs, as well as large cholangiocyte H2HR signaling during 
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